Evidence map›Paper›PMID 36421267›Full record

ReviewAntibiotics (Basel, Switzerland)2022

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation.

Anna Starshinova, Irina Dovgalyk, Ekaterina Belyaeva, Anzhela Glushkova, Nikolay Osipov, Dmitry Kudlay

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Anna StarshinovaAlmazov National Medical Research Centre, 197341 Saint-Petersburg, Russia.ORCID 0000-0002-9023-6986
Irina DovgalykSt. Petersburg Research Institute of Phthisiopulmonology, 191036 Saint-Petersburg, Russia.
Ekaterina BelyaevaRepublic TB Healthcare Dispensary, 185032 Petrozavodsk, Russia.
Anzhela GlushkovaV.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, 192019 Saint-Petersburg, Russia.
Nikolay OsipovSt. Petersburg Department of Steklov Mathematical Institute of Russian Academy of Sciences, 191023 Saint-Petersburg, Russia.
Dmitry KudlayFederal State Autonomous Educational Institution of Higher Education "First Moscow State Medical University Named after I.I. THEM. Sechenov" of the Ministry of Health of Russia (Sechenov University), St. Trubetskaya 8, Building 2, 119048 Moscow, Russia.ORCID 0000-0003-1878-4467
Federal Almazov North-West Medical Research Centre · RURussian Academy of Sciences · RUSaint-Petersburg Research Institute of Phthisiopulmonology · RUSechenov University · RUSt.Petersburg V.M.Bekhterev Psychoneurological Research Institute · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the conditions of the continued growth of multiple- and extensive drug-resistant tuberculosis, use of the new highly effective anti-tuberculosis drugs in this patient category is of great relevance. The aim of the study was determination the efficacy of treatment in patients with multidrug- and extensive drug-resistant tuberculosis using bedaquiline based on studies published in the Russian Federation. MATERIALS AND

methodsThe authors analyzed data published in studies from 2014 to 2022; 41 publications were included in total and 17 articles corresponded to the study design. The results of treatment of 1404 tuberculosis patients with MDR/XDR TB were described. Bedaquiline was used according to the standard scheme with a description of the treatment results after 24-26 weeks. Treatment efficacy was estimated according to accepted criteria. RESULTS OF THE STUDY: The analysis showed that the treatment efficacy on conversion was achieved in 79.5% of cases (95% Cl 76.5-82.3), and recovery was observed in 82.0% of cases (95% Cl 78.6-85.1). Departure from the therapy was observed in rare cases (9.8%; 95% Cl 7.9-12.2). Deaths were recorded in 6.5% of cases (95% Cl 4.9-8.3), which were associated with the severe disease and concomitant pathology in 74.3%. The development of adverse events was noted in half of the patients (55.7%); however, bedaquiline cancellation occurred in a few cases (7.0%; 95% Cl 3.0-13.0). From analyzing data in patients with MDR and XDR TB, the efficacy of treatment was 89.9% (95% Cl 85.9-93.2) and 71.9% (95% Cl 66.2-77.1), respectively.

conclusionUse of bedaquiline in treatment makes it possible to achieve recovery of patients with MDR/XDR TB in 82.0% of cases with patients dropping out of treatment in 9.8%. At the same time, in patients with MDR TB, recovery was achieved in 89.9% of cases, while in patients with XDR TB, 71.9% of cases recovered.

Indexed as

bedaquilineextensive drug resistancemultidrug resistancemycobacterium tuberculosistreatment efficacytuberculosis

Identifiers

PMID36421267
PMCPMC9686766
OpenAlexW4309214715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.